First AD

Second AD

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer.

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

Video content above is prompted by the following question(s):

Please discuss your general approach to using neoadjuvant therapy to escalate or deescalate therapy for patients?

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice

Peer Exchange

Baylor Scott & White Charles A. Sammons Cancer Center 

Cancer Centers

Partner

UCLA Health Jonsson Comprehensive Cancer Center

Yale Cancer Center

VCU Massey Cancer Center

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Challenges in Diagnosing HER2+ Breast Cancer

Preoperative Monitoring and Surgical Options for HER2+ Patients

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

Overview of DESTINY-Breast06

Clinical Perspectives on Managing ILD Related to T-DXd

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

Unmet Needs and Future Direction in HER2+ Breast Cancer